Paliperidone Long-Acting Injections in Huntington's Disease for Motor and Behavioural Disturbances.
Administration, Oral
Antipsychotic Agents
/ administration & dosage
Delayed-Action Preparations
/ administration & dosage
Female
Humans
Huntington Disease
/ diagnosis
Injections, Intramuscular
Mental Disorders
/ diagnosis
Middle Aged
Motor Disorders
/ diagnosis
Paliperidone Palmitate
/ administration & dosage
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
28
2
2019
medline:
24
5
2019
entrez:
28
2
2019
Statut:
ppublish
Résumé
Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington's disease (HD). However, patients with behavioural disturbances are often non-compliant, thus the oral route is inappropriate. The effects of antipsychotic long-acting injections (LAI) in HD are significantly underrepresented in literature. Paliperidone LAI (P-LAI), an atypical antipsychotic, has benefits over other antipsychotics LAI with its long dosing interval and no initial oral overlap, but has no documented cases for this indication. This case of a 45-year-old female highlights the use of P-LAI for severe aggression and chorea secondary to HD causing failed placement in assisted-care accommodation and mobility via an electronic-wheelchair. Three weeks after commencing treatment, she could walk unassisted, and displayed no aggression. After 10 months, she still had significant improvements and resided in the same accommodation for 6 months without any concern. Thus, this case suggests that P-LAI may be a treatment option for non-compliant HD patients.
Identifiants
pubmed: 30810915
doi: 10.1007/s40261-019-00759-8
pii: 10.1007/s40261-019-00759-8
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Paliperidone Palmitate
R8P8USM8FR
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
407-410Références
Hum Psychopharmacol. 2005 Jan;20(1):41-5
pubmed: 15565639
J Psychopharmacol. 2008 May;22(3):238-43
pubmed: 18541624
PLoS Curr. 2011 Aug 30;3:RRN1260
pubmed: 21975581
Front Neurosci. 2013 Jul 04;7:114
pubmed: 23847463
Ann Clin Psychiatry. 2008 Jan-Mar;20(1):1-3
pubmed: 18297579
Int Clin Psychopharmacol. 2011 Mar;26(2):114-9
pubmed: 21119522
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
Drugs R D. 2015 Jun;15(2):163-74
pubmed: 25943458